Recombinant human anti-EGFR mAB (Simcere)

重组全人源抗EGFR单克隆抗体（先声药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human anti-EGFR mAB (Simcere)
Drug Alias Name重组全人源抗EGFR单抗注射液（先声药业）Recombinant fully human anti-EGFR mAb (Simcere)重组全人源抗EGFR单克隆抗体注射液（先声药业）Recombinant human anti-EGFR monoclonal antibody (Simcere)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesJiangsu Simcere Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShandong Xiansheng Zaiming Biopharmaceutical Co LtdJiangsu Simcere Pharmaceutical Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A